|
T.TH
|
Responding to the question on how long a 1b could drag on, while I have no...
|
|
T.TH
|
I think it means success in oncology will take care of NASH. Need to...
|
|
T.TH
|
This is what I have seen in other trials. As stated, you cannot stop given...
|
|
T.TH
|
Scarlet is the resident dosage expert, but if I understand it, the 420mg...
|
|
T.TH
|
Least we forget, their newest invstor is now on the shareholder's side of...
|
|
T.TH
|
The last of the 2021 sellers are squeezing out. Painful on these incredibly...
|
|
T.TH
|
Thanks for that info. I guess you don't need as much of it, but you have...
|
|
T.TH
|
My wholly non-scientific conjecture is that the did the initial generic and...
|
|
T.TH
|
Omicron is really screwing things up again. Darn...! Sqidmandon wrote: I...
|
|
T.TH
|
If the SORT1 platform proves itself up over the next year, THTX would be...
|
|
T.TH
|
Seems they've taken down the Jul 19 investor presentation. Have to assume...
|
|
T.TH
|
Need more chunky bids. Volumes still quite low for a company about to start...
|
|
T.TH
|
Similar down this way --new year, new contribution amounts. We may not get...
|
|
T.TH
|
One thing I've learned over the years watching managements is that new...
|
|
T.TH
|
Can't diagree. I also hadn't thought that they will just...
|
|
T.TH
|
Stocks up around 10% from the recent low, around beginning of month, on a...
|
|
T.TH
|
Hopefully they hand out samples /s stephanedodier wrote: Here is the...
|
|
T.TH
|
The death knell for FXR agonist approach it seems. As SPCEO points out, the...
|
|
T.TH
|
He's also a McGill grad and up in Montreal for JPM -- so likely part of...
|
|
T.TH
|
Commercial banker in lifesci --so loans and services, not on the investment...
|